Organization

GENXPRO GMBH

Frankfurt biotech SME providing transcriptomics and gene expression profiling services to European research consortia, with growing focus on computational oncology.

Technology SMEhealthDESMENo active H2020 projectsThin data (2/5)

H2020 projects

As coordinator

Total EC funding

€984K

Unique partners

What they do

Their core work

GenXPro is a Frankfurt-based biotechnology SME specializing in transcriptomics and gene expression profiling technologies. They provide advanced sequencing and molecular analysis services to research consortia studying diverse biological systems — from bacterial adaptation and brain barriers to cancer progression. Their core contribution to EU projects is generating and analyzing large-scale transcriptomic datasets that help consortium partners understand molecular mechanisms underlying disease and biological processes.

Core expertise

What they specialise in

Transcriptomics and gene expression analysisprimary

3 projects

Central to all three H2020 projects (List_MAPS, BtRAIN, REVERT), providing transcriptomic profiling across diverse biological domains.

Cancer biology and computational oncologyemerging

1 project

REVERT project focuses on predictive models, computational frameworks, and AI-based decision support for colorectal cancer therapy.

Microbial adaptation and proteomicssecondary

1 project

List_MAPS project studied Listeria monocytogenes adaptation through proteomic and transcriptomic deep sequencing.

Neuroscience and blood-brain barrier researchsecondary

1 project

BtRAIN project on brain barrier training, likely contributing molecular profiling of barrier function.

Evolution & trajectory

How they've shifted over time

Early focus

Fundamental biology training networks

Recent focus

Computational oncology and AI therapeutics

GenXPro's early H2020 work (2015-2019) centered on MSCA training networks in fundamental biology — bacterial adaptation (List_MAPS) and neuroscience (BtRAIN) — where they served as a technology provider for transcriptomic analysis. Their most recent project (REVERT, 2020-2024) marks a clear pivot toward applied health, combining their molecular profiling expertise with computational modeling, AI-based decision support, and targeted cancer therapy. This shift from basic research service provider to active contributor in translational oncology represents a significant evolution in ambition and application scope.

GenXPro is moving from pure transcriptomics services toward integrated computational biology and AI-driven clinical applications, particularly in cancer — expect them to seek projects combining molecular data with predictive modeling.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European15 countries collaborated

GenXPro operates exclusively as a participant, never coordinating projects — consistent with their role as a specialist technology provider embedded in larger research consortia. With 51 unique partners across 15 countries from just 3 projects, they integrate into large, diverse networks (typical of MSCA training networks). This pattern suggests they are a reliable, low-friction partner that delivers specific technical capabilities without requiring project leadership responsibilities.

Despite only three projects, GenXPro has built a broad European network of 51 partners across 15 countries, largely through participation in large MSCA training networks. Their geographic reach is pan-European with no apparent regional concentration.

Why partner with them

What sets them apart

GenXPro occupies a rare niche as a private SME offering industrial-grade transcriptomics services to academic-led consortia — bridging the gap between commercial sequencing capacity and research-driven experimental design. Their ability to contribute meaningfully across completely different biological domains (microbiology, neuroscience, oncology) demonstrates genuine platform versatility rather than narrow specialization. For consortium builders, they offer a tested commercial partner with proven ability to deliver molecular profiling within EU project timelines and reporting structures.

Notable projects

Highlights from their portfolio

REVERT
Their largest funded project (€443,750) and a strategic shift into AI-driven colorectal cancer therapy — combining molecular profiling with computational frameworks and predictive models.
List_MAPS
Demonstrates GenXPro's versatility — applying transcriptomics to food safety microbiology (Listeria adaptation), a domain far removed from their later cancer focus.
BtRAIN
Brain barriers training network connecting GenXPro to neuroscience research networks across Europe, expanding their partner base significantly.

Cross-sector capabilities

Food safety and microbial genomicsNeuroscience and brain researchArtificial intelligence for biomedical applicationsTraining and capacity building (MSCA networks)

Analysis note: Profile based on only 3 projects with limited keyword data for the earlier two (List_MAPS, BtRAIN). GenXPro's core technology (likely MACE transcriptomics) is inferred from their company name and the consistent molecular profiling role across diverse biological domains, but specific technical capabilities are not fully documented in the H2020 data. The evolution toward computational oncology is real but based on a single project (REVERT).